Uno studio su Seltorexant rispetto a Quetiapina XR come terapia aggiuntiva agli antidepressivi in partecipanti adulti e anziani con disturbo depressivo maggiore con sintomi di insonnia che hanno risposto in modo inadeguato alla terapia antidepressiva
Studio in doppio cieco, randomizzato, a gruppi paralleli con quetiapina a rilascio prolungato come confronto per valutare l'efficacia e la sicurezza di seltorexant 20 mg come terapia aggiuntiva agli antidepressivi in pazienti adulti e anziani con disturbo depressivo maggiore con sintomi di insonnia che hanno risposto in modo inadeguato alla terapia antidepressiva
The purpose of this study is to assess the efficacy of seltorexant compared with quetiapine extended-release (XR) as adjunctive therapy to an antidepressant drug in treatment response in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Major depressive disorder (MDD) is a common, serious, recurrent disorder. Seltorexant (JNJ-42847922) is a potent and selective antagonist of the human orexin-2 receptor (OX2R) that is being developed for the adjunctive treatment of MDDIS. The hypothesis for this study is that seltorexant is superior to quetiapine XR in leading to a response after 26 weeks of treatment (greater than or equal to [>=] 50 percent [%] improvement on baseline Montgomery Asberg Depression Rating Scale [MADRS] total score), when administered as adjunctive treatment to an antidepressant in adult and elderly participants with MDDIS who have had an inadequate response to treatment with an SSRI/SNRI. The study will be conducted in 3 phases: a screening phase (up to 30 days), a double-blind (DB) treatment phase (26 weeks), and a post treatment follow-up phase (7 to 14 days after the end of DB treatment phase for all participants, and up to 196 days from baseline for participants who stop study treatment early). The total study duration for each participant will be approximately 32 weeks. Efficacy, safety, pharmacokinetics, and biomarkers will be assessed at specified time points during this study.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Buenos Aires, Argentina, 1058AAJ
- CENydET - Centro Neurobiologico y de Stress Traumatico
-
Buenos Aires, Argentina, C1405BOA
- FunDaMos
-
Buenos Aires, Argentina, 1199
- Hospital Italiano
-
Ciudad Autonoma Buenos Aires, Argentina, C1428AQK
- Hospital Fleni
-
Córdoba, Argentina, X5004AOA
- Instituto Privado Kremer
-
Córdoba, Argentina, 5000
- Fundacion Lennox
-
Córdoba, Argentina, X5006IKK
- Centro Medico Luquez
-
La Plata, Argentina, Thanks
- Clinica Privada de Salud Mental Santa Teresa de Ávila
-
La Plata, Argentina, 1902
- CENPIA
-
Mendoza, Argentina, M5502AWY
- CENAIN
-
San Miguel de Tucumán, Argentina, 4000
- Clinica Mayo de UMCB
-
-
-
-
-
Bruges, Belgio, 8310
- AZ Sint-Lucas
-
Sint-Niklaas, Belgio, 9100
- AZ Nikolaas
-
-
-
-
-
Pleven, Bulgaria, 5800
- Medical Center Medconsult-Pleven
-
Plovdiv, Bulgaria, 4028
- MC 'Hipokrat - N', EOOD
-
Rousse, Bulgaria, 7003
- Mental Health Center - Rousse
-
Sofia, Bulgaria, 1680
- Medical Center Intermedica, OOD
-
Sofia, Bulgaria, 1113
- Medical Center St. Naum
-
Sofia, Bulgaria, 1784
- MC 'Synexus Sofia' EOOD
-
Stara Zagora, Bulgaria, 6003
- UMHAT Prof. Dr. St. Kirkovich AD
-
Stara Zagora, Bulgaria, 6000
- MC 'Synexus Sofia' EOOD
-
Tzarev Brod, Bulgaria, 9747
- State Psychiatric Hospital - Tzarev Brod
-
Varna, Bulgaria, 9020
- Diagnostic Consulting Center Mladost - M Varna
-
Veliko Tarnovo, Bulgaria, 5000
- Mental Health Center - Veliko Tarnovo EOOD
-
-
-
-
Nova Scotia
-
Sydney, Nova Scotia, Canada, B1P 1E1
- A.K. Munshi Medical Inc.
-
-
Ontario
-
Toronto, Ontario, Canada, M3J 2C5
- Canadian Phase Onward
-
-
Quebec
-
Montreal, Quebec, Canada, H1M 1B1
- Clinique Force Medic (GCP Trials)
-
-
-
-
-
Brno, Cechia, 60200
- Psychiatricka ambulance Saint Anne s.r.o.
-
Hradec Králové, Cechia, 500 09
- NeuropsychiatrieHK, s.r.o.
-
Pilsen, Cechia, 301 00
- A Shine S R O
-
Prague, Cechia, 100 00
- Clintrial s r o
-
Prague, Cechia, 160 00
- NeuropsychiatrieHK, s.r.o.
-
Prague, Cechia, 10000
- AD71 s.r.o.
-
Prague, Cechia, 186 00
- Institut Neuropsychiatricke pece
-
-
-
-
-
Jelgava, Lettonia, LV-3008
- The Mental Hospital of Jelgava Ģintermuiža - Psychiatry
-
Liepāja, Lettonia, LV-3401
- L. Keruze Practice in Psychiatry
-
Outpatient Centre of Psychiatry, Lettonia, LV-4601
- Hospital of Rezekne
-
Riga, Lettonia, LV-1002
- Riga Centre of Psychiatry and Narcology
-
-
-
-
-
Kaunas, Lituania, 48259
- Kaunas Silainiu Outpatient Clinic, Public Institution
-
Kaunas, Lituania, 53136
- Republic Kaunas Hospital
-
Kaunas, Lituania, LT-44279
- Romuvos Klinika, JSC
-
Kaunas, Lituania, LT-50009
- Hospital of Lithuanian University of Health Sciences Kaunas Clinics
-
Vilnius, Lituania, 09112
- Zirmunai Mental Health Center, Public Institution
-
Vilnius, Lituania, 10309
- Vilnius Mental Health Center
-
Vilnius, Lituania, 10204
- Antakalnis Psychiatric Consultation Centre, Public Institution
-
Šilutė, Lituania, 99176
- Medical Center Puriena JSC
-
-
-
-
-
Ipoh, Malaysia, 30990
- Hospital Raja Permaisuri Bainun
-
Johor Bahru, Malaysia, 81200
- Hospital Permai
-
Pulau Pinang, Malaysia, 10990
- Hospital Pulau Pinang
-
Seremban, Malaysia, 70300
- Hospital Tuanku Jaafar
-
-
-
-
-
Bełchatów, Polonia, 97-400
- Gabinet Lekarski Psychiatryczny Ireneusz Kaczorowski
-
Bialystok, Polonia, 15-464
- Wlokiennicza MED Specjalistyczna Praktyka Lekarska dr n.med. Tomasz Markowski
-
Bydgoszcz, Polonia, 85-080
- Przychodnia Srodmiescie SP. z o.o.
-
Gdansk, Polonia, 80 546
- Centrum Badan Klinicznych PI House sp z o o
-
Lodz, Polonia, 90-009
- Specjalistyczna Indywidualna Praktyka Lekarska
-
Lodz, Polonia, 90-368
- CCBR - Lodz - PL
-
Lublin, Polonia, 20-582
- Specjalistyczna Praktyka Lekarska Marek Domanski
-
Poznan, Polonia, 60-702
- Synexus Polska Sp. z.o.o. Oddzial w Poznaniu
-
Warsaw, Polonia, 01 737
- Specjalistyczny Osrodek Medycyny Wieku Dojrzalego Sp z o.o.
-
Warsaw, Polonia, 02 957
- Instytut Psychiatrii I Neurologii
-
-
-
-
-
Derby, Regno Unito, DE22 3LZ
- Kingsway Hospital
-
Greater Manchester, Regno Unito, M15 6SX
- Synexus
-
Harrogate, Regno Unito, HG1 2PW
- Garden Valleys Resource Centre
-
London, Regno Unito, SE5 8EF
- Kings College Hospital NHS Trust
-
Redruth, Regno Unito, TR15 2SP
- Cornwall Partnership Foundation Trust
-
-
-
-
-
Engel's, Russia, 413124
- Engels psychiatric hospital
-
Kemerovo, Russia, 650036
- Kemerovo Regional Clinical Psychiatric Hospital
-
Lipetsk Region, Russia, 399313
- GUZ Lipetsk Regional psychoneurological Hospital #1
-
Moscow, Russia, 105082
- JSC Scientific Centre of Personalized Medicine
-
Moscow, Russia, 107076
- FSI Moscow SRI of Psychiatry of Minzdravsocrazvitia
-
Moscow, Russia, 107076
- Moscow Scientific Research Institute of Psychiatry
-
Omsk, Russia, 644070
- Clinical Psychiatry Hospital n.a. N.N. Solodovnikov
-
Saint Petersburg, Russia, 192019
- St-Petersburg Bekhterev Psychoneurological Research Institute
-
Tomsk, Russia, 634009
- Klinika StoLet Ltd
-
Yekaterinburg, Russia, 620030
- Sverdlov Regional Psychiatric Clinical Hospital
-
-
-
-
-
Belgrade, Serbia, 11000
- University Clinical Center of Serbia
-
Belgrade, Serbia, 11000
- General Hospital Euromedik
-
Belgrade, Serbia, 11000
- University Clinical Hospital Center Dr Dragisa Misovic- Dedi
-
Belgrade, Serbia, 11000
- General Hospital Acibadem Bel Medic
-
Belgrade, Serbia, 11000
- Institute of Mental Health Serbia
-
Kovin, Serbia, 26220
- Special Neuropsychiatric Hospital Kovin
-
Kragujevac, Serbia, 34000
- University Clinical Center Kragujevac
-
Niš, Serbia, 18000
- Clinical Center Nis
-
Novi Kneževac, Serbia, 23330
- Specialized Hospital for Neuropsychiatric Diseases Sveti Vracevi
-
-
-
-
-
Banská Bystrica, Slovacchia, 97401
- Psychomed-Svatosavsky, s.r.o.
-
Bojnice, Slovacchia, 97201
- Nemocnica s poliklinikou Prievidza so sidlom v Bojniciach
-
Košice, Slovacchia, 040 11
- Epamed sro
-
Liptovský Mikuláš, Slovacchia, 03123
- Liptovska Nemocnica S Poliklinikou Mudr. Ivana Stodolu
-
Rimavská Sobota, Slovacchia, 97901
- Psychiatricka Ambulancia Psycholine S.R.O.
-
Trenčín, Slovacchia, 91101
- FN Trencin
-
Trenčín, Slovacchia, 91108
- Pro mente sana s.r.o.
-
Žilina, Slovacchia, 1207
- Fakultna nemocnica s poliklinikou v Ziline
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35233
- University of Alabama at Birmingham
-
-
Arizona
-
Tucson, Arizona, Stati Uniti, 85712
- SW Biomedical Research LLC
-
-
California
-
Culver City, California, Stati Uniti, 90230
- Proscience Research Group
-
Encino, California, Stati Uniti, 91316
- Pharmacology Research Institute
-
Garden Grove, California, Stati Uniti, 92845
- Collaborative NeuroScience Network
-
Long Beach, California, Stati Uniti, 90806
- Collaborative NeuroScience Network
-
Los Alamitos, California, Stati Uniti, 90720
- Pharmacology Research Institute
-
Los Angeles, California, Stati Uniti, 90025
- CalNeuro Research
-
Newport Beach, California, Stati Uniti, 92660
- Pharmacology Research Institute
-
Orange, California, Stati Uniti, 92868
- NRC Research Institute
-
Orange, California, Stati Uniti, 92868
- Pacific Neuropsychiatric Specialists
-
Pico Rivera, California, Stati Uniti, 90660
- CNRI-Los Angeles, LLC
-
Rancho Cucamonga, California, Stati Uniti, 91730
- Prospective Research Innovations Inc
-
Redlands, California, Stati Uniti, 92374
- Anderson Clinical Research
-
San Diego, California, Stati Uniti, 92103
- University of California at San Diego
-
Santa Ana, California, Stati Uniti, 92705
- CI Trials
-
Santa Ana, California, Stati Uniti, 91704
- National Research Institute
-
Santee, California, Stati Uniti, 92071
- CMB Clinical Trials
-
Sherman Oaks, California, Stati Uniti, 91403
- Schuster Medical Research Institute
-
Upland, California, Stati Uniti, 91786
- Pacific Clinical Research Medical Group
-
-
Connecticut
-
Hartford, Connecticut, Stati Uniti, 06102
- Hartford Hospital
-
-
Florida
-
Doral, Florida, Stati Uniti, 33166
- Moonshine Research Center, Inc
-
Hallandale, Florida, Stati Uniti, 33009
- Velocity Clinical Research, Hallandale Beach
-
Hialeah, Florida, Stati Uniti, 33012
- Indago Research & Health Center Inc
-
Hialeah, Florida, Stati Uniti, 33012
- New Life Medical Research Center, Inc.
-
Hialeah, Florida, Stati Uniti, 33013
- Amedica Research Institute Inc
-
Lakeland, Florida, Stati Uniti, 33803
- Meridien Research
-
Miami, Florida, Stati Uniti, 33122
- Premier Clinical Research
-
Miami, Florida, Stati Uniti, 33125
- Global Medical Institutes
-
Miami, Florida, Stati Uniti, 33137
- Miami Jewish Health System
-
Orlando, Florida, Stati Uniti, 32806
- Synexus Research Orlando
-
Orlando, Florida, Stati Uniti, 23801
- Clinical Neuroscience Solutions
-
Tampa, Florida, Stati Uniti, 33612
- University of South Florida
-
The Villages, Florida, Stati Uniti, 32162
- Compass Research LLC-Bioclinica Research
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30331
- Atlanta Center for Medical Research
-
Atlanta, Georgia, Stati Uniti, 30328
- Synexus Clinical Research US Inc
-
Decatur, Georgia, Stati Uniti, 30030
- iResearch Atlanta LLC
-
Marietta, Georgia, Stati Uniti, 30060
- Psych Atlanta, P.C.
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60634
- Chicago Research Center
-
Libertyville, Illinois, Stati Uniti, 60048
- Capstone Clinical Research
-
Lisle, Illinois, Stati Uniti, 60532
- Alexian Brothers Health System
-
Naperville, Illinois, Stati Uniti, 60563
- Baber Research Group
-
Oakbrook Terrace, Illinois, Stati Uniti, 60618
- Lemah Creek Clinical Research
-
-
Kansas
-
Wichita, Kansas, Stati Uniti, 67214
- Ascension via Christi Research
-
-
Louisiana
-
New Orleans, Louisiana, Stati Uniti, 70115
- Riverstar Research
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21208
- Pharmasite Research, Inc.
-
-
Massachusetts
-
New Bedford, Massachusetts, Stati Uniti, 02740
- BTC of New Bedford
-
Roslindale, Massachusetts, Stati Uniti, 02135
- Boston Clinical Trials & Medical Research
-
-
Missouri
-
O'Fallon, Missouri, Stati Uniti, 63368
- Psychiatric Care and Research Center (PCRC)
-
-
New Jersey
-
Toms River, New Jersey, Stati Uniti, 08755
- Bio Behavioral Health
-
-
New York
-
Brooklyn, New York, Stati Uniti, 11235
- SPRI Clinical Trials, LLC
-
New York, New York, Stati Uniti, 10128
- The Medical Research Network, LLC
-
New York, New York, Stati Uniti, 10017
- Fieve Clinical Research Inc
-
Rochester, New York, Stati Uniti, 14618 1609
- Finger Lakes Clinical Research
-
Staten Island, New York, Stati Uniti, 10312
- Richmond Behavioral Associates
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27701
- Velocity Clinical Research, Inc.
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45219
- University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience
-
Dayton, Ohio, Stati Uniti, 45417
- Midwest Clinical Research Center
-
North Canton, Ohio, Stati Uniti, 44720
- Neuro Behavioral Clinical Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73112
- Sooner Clinical Research
-
Oklahoma City, Oklahoma, Stati Uniti, 73118
- Paradigm Research Professionals, LLC
-
-
Pennsylvania
-
Pine Hill, Pennsylvania, Stati Uniti, 08021
- Suburban Research Associates
-
Scranton, Pennsylvania, Stati Uniti, 18503
- Global Medical Institutes
-
-
South Carolina
-
Mt. Pleasant, South Carolina, Stati Uniti, 29464
- Coastal Carolina Research Center
-
-
Texas
-
Bellaire, Texas, Stati Uniti, 77401
- West Houston Clinical Research Service
-
Fort Worth, Texas, Stati Uniti, 76104
- North Texas Clinical Trials
-
Mansfield, Texas, Stati Uniti, 76054
- Hawkins Psychiatry, PC
-
The Woodlands, Texas, Stati Uniti, 77381
- Family Psychiatry of The Woodlands
-
Wichita Falls, Texas, Stati Uniti, 76309
- Grayline Research Center
-
-
Utah
-
Clinton, Utah, Stati Uniti, 84015
- Alpine Research Organization
-
Draper, Utah, Stati Uniti, 84020
- Cedar Clinical Research
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22903
- University of Virginia
-
-
Washington
-
Bellevue, Washington, Stati Uniti, 98007
- Northwest Clinical Research Center
-
Everett, Washington, Stati Uniti, 98201
- Core Clinical Research
-
-
Wisconsin
-
Waukesha, Wisconsin, Stati Uniti, 53188
- Cary J. Kohlenberg, MD, SC, dba, IPC Research.
-
-
-
-
-
Hlevakha, Ucraina, 8631
- MNCE of Kyiv RC Regional Psychiatric and Narcological Medical Association
-
Kharkiv, Ucraina, 61068
- Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3'
-
Kyiv, Ucraina, 04080
- Kyiv Territorial Medical Incorporation 'Psychiatry'
-
Kyiv, Ucraina, 1030
- Railway Clinical Hospital #1 of Kiev Railway station of DTGO 'South-Western Railway'
-
Kyiv, Ucraina, 1034
- Medical Center Health and Happy
-
Nove, Ucraina, 25491
- Mnpe 'Regional Clinical Psychiatric Hospital of Kirovohrad Regional Council'
-
Ternopil, Ucraina, 46020
- Ternopil RCCPH Depts of Psychiatry #2 (m) & Psychiatry #4 (f) Ternopil I.Ya. Gorbachevskyi SMU
-
Zaporizhzhya, Ucraina, 69600
- Zaporizhzhia Regional Clinical Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Meet diagnostic and statistical manual of mental disorders-5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the structured clinical interview for DSM-5 Axis I disorders-clinical trials version (SCID-CT) diagnosed with first depressive episode prior to age 60. The length of the current depressive episode must be less than or equal to (<=) 24 months
- Have had an inadequate response to at least 1 but no more than 2 antidepressants, administered at an adequate dose and duration in the current episode of depression. The current antidepressant cannot be the first antidepressant treatment for the first lifetime episode of depression. An inadequate response is defined as less than (<) 50 percent (%) reduction but with some improvement (that is, improvement greater than [>] 0%) in depressive symptom severity with residual symptoms present other than insomnia, and overall good tolerability, as assessed by the Massachusetts General Hospital-Antidepressant Treatment Response Questionnaire (MGH-ATRQ)
- Is receiving and tolerating well any one of the following selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for depressive symptoms at screening, in any formulation and available in the participating country: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at or above therapeutic dose level) for at least 6 weeks, and for no greater than 18 months in the current episode
- Have a hamilton depression rating scale (HDRS)-17 total score greater than or equal to (>=) 20 at the first screening interview, must not demonstrate a clinically significant improvement (that is, an improvement of > 20% on their HDRS-17 total score) from the first to the second independent HDRS-17 rating, and must have a HDRS-17 total score >18 at the second screening interview
- Have a patient version insomnia severity index (ISI) total score >= 15 as well as a clinician version of the ISI total score >= 15 at the second screening visit
- Body mass index (BMI) between 18 and 40 kilogram per meter square (kg/m^2), inclusive (BMI=weight/height^2)
- Participant must be medically stable on the basis of the following: physical examination, vital signs (including blood pressure), and 12-lead electrocardiogram (ECG) performed at screening and baseline
Exclusion Criteria:
- Has a recent (last 3 months) history of, or current signs and symptoms of, severe renal insufficiency (creatinine clearance [CrCl] less than [<] 30 milliliter per minute [mL/min]); clinically significant or unstable cardiovascular, respiratory, gastrointestinal, neurologic, hematologic, rheumatologic, immunologic or endocrine disorders. uncontrolled Type 1 or Type 2 diabetes mellitus
- Has a history of treatment-resistant MDD, defined as a lack of response to 2 or more adequate antidepressant treatments in the current episode, as indicated by no or minimal (<25% improvement in symptoms) when treated with an antidepressant of adequate dose (per MGH-ATRQ) and duration (at least 6 weeks)
- Has history or current diagnosis of a psychotic disorder, bipolar disorder, intellectual disability, autism spectrum disorder, borderline personality disorder, somatoform disorders
- Has a history of moderate to severe substance use disorder including alcohol use disorder according to DSM-5 criteria within 6 months before screening
- Has any significant primary sleep disorder, including but not limited to obstructive sleep apnea, restless leg syndrome, or parasomnias. Participants with insomnia disorder are allowed
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Seltorexant
Adult participants will receive seltorexant once daily from Day 1-7 and together with matching placebo from Day 8 till Day 182. Elderly participants will receive seltorexant once daily from Day 1-3 and together with matching placebo from Day 4 till Day 182. |
Participants will receive seltorexant over-encapsulated tablet orally. Participants will receive placebo over-encapsulated tablet matching to seltorexant orally. |
|
Comparatore attivo: Quetiapine Extended-Release (XR)
Adult participants will receive quetiapine XR once daily from Day 1-2, followed by an increase in dose from Day 3-7, and from Day 8-14 together with matching placebo. After Day 14, quetiapine XR twice daily from Day 14 till Day 182. Elderly participants will receive quetiapine XR once daily from Day 1-3 and twice from Day 4-7, followed by an increase in dose once daily from Day 8-14 together with matching placebo. After Day 14 till Day 182, quetiapine XR will be adjusted by investigator based on the participant's clinical response and tolerability. |
Participants will receive quetiapine XR capsule orally. Participants will receive placebo capsule matching to quetiapine XR orally. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Participants Who Achieved Response (Greater Than or Equal to [>=50] Percent Improvement in Montgomery-Asberg Depression Rating Scale [MADRS] Total Score From Baseline) at Week 26
Lasso di tempo: Week 26
|
Percentage of participants who achieved response at Week 26 was reported. Responders were defined as participants with >= 50 percent (%) improvement in the MADRS total score from baseline. MADRS was a clinician-administered scale designed to measure depression severity and detected changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Week 26
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change From Baseline to Week 26 in Weight
Lasso di tempo: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in weight was reported. |
Baseline (Day 1) and Week 26
|
|
Time to Potentially Treatment Related Discontinuation of Study Drug
Lasso di tempo: From first dose of study drug (Day 1) up to Week 30
|
Time to potentially treatment related discontinuation of study drug was reported. Time to discontinuation of study drug was defined as the number of days from the first dose of study drug to the last dose of study drug. Potentially treatment related discontinuation of study drug was defined as all study drug discontinuations excluding the potentially non-treatment related discontinuations (such as, loss of insurance for antidepressant therapy, movement/travel out of the area, change of work-schedule being unable to accommodate visit schedule, family circumstances, site terminated by sponsor, study terminated by sponsor). Kaplan-Meier estimate was used. |
From first dose of study drug (Day 1) up to Week 30
|
|
Change From Baseline to Week 26 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Lasso di tempo: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in MADRS total score were reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Baseline (Day 1) and Week 26
|
|
Change From Baseline to Week 26 in MADRS-6 Total Score
Lasso di tempo: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in MADRS-6 total score was reported. The MADRS-6 scale was a clinician-administered questionnaire used to measure the severity of MDD symptoms. The MADRS-6 scale was a subset of the MADRS-10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), the overall score ranged from 0 to 36, higher scores represented a more severe condition. |
Baseline (Day 1) and Week 26
|
|
Change From Baseline to Week 26 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score
Lasso di tempo: Baseline (Day 1) and Week 26
|
The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items (apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement. |
Baseline (Day 1) and Week 26
|
|
Change From Baseline to Week 26 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score
Lasso di tempo: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in PHQ-9 total score was reported. The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) major depressive disorder (MDD) criteria. Each item was rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. Negative changes in PHQ-9 total score indicated improvement. |
Baseline (Day 1) and Week 26
|
|
Percentage of Participants With MADRS Total Score Less Than or Equal to (<=) 12 at Week 26
Lasso di tempo: Week 26
|
Percentage of participants with MADRS total score <=12 at Week 26 was reported. A participant was defined as a remitter at a given time point if the MADRS total score was <=12 at that time point. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Week 26
|
|
Percentage of Participants With a >=50 Percent Improvement in MADRS Total Score and MADRS <=18 at Week 26
Lasso di tempo: Week 26
|
Percentage of participants with a >=50 percent improvement in MADRS total score and MADRS <=18 at Week 26 was reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Week 26
|
|
Percentage of Participants With >=7 Percent Weight Increase From Baseline at Week 26
Lasso di tempo: Week 26
|
Percentage of participants with >=7 percent weight increase from baseline at Week 26 was reported. |
Week 26
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CR108810
- 42847922MDD3005 (Altro identificatore: Janssen Research & Development, LLC)
- 2020-000341-14 (Numero EudraCT)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .